Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 0.7%

EW opened at $92.96 on Thursday. The firm’s fifty day simple moving average is $88.52 and its 200 day simple moving average is $84.26. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a market capitalization of $53.53 billion, a P/E ratio of 53.43, a P/E/G ratio of 2.35 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on EW shares. Robert W. Baird upped their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $1,274,082,000. Norges Bank bought a new stake in Edwards Lifesciences in the fourth quarter valued at $803,686,000. Deutsche Bank AG bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.